Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 8/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PYGM | P11217 | 3/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28824001 | 0.84 | CDA (0.41) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL25380036 | 0.77 | CDA (0.44) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL25381411 | 0.77 | P2RY2 (0.53) | — | |
| SCHEMBL28580471 | 0.74 | CDA (0.46) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL21283173 | 0.73 | CDA (0.47) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL25458669 | 0.73 | PYGM (0.44) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15972109 | 0.72 | TP53 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3MAPT | |
| SCHEMBL15972112 | 0.72 | TP53 (0.43) | SLC28A1SLC28A2SLC29A1SLC28A3MAPT | |
| SCHEMBL18871272 | 0.71 | CDA (0.48) | CDASLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL31096857 | 0.68 | CDA (0.42) | CDASLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929288-A | Synthetic modified RNA and uses thereof | 西奈山伊坎医学院 | 2022-08-19 | — | — | CN | disclosed |